Methods of reducing risk of major adverse cardiovascular events in primary preventive subjects
By administering RNAi agents with specific nucleotide sequences to high LDL-C subjects who had not experienced ASCVD events, the PCSK9 protein level was reduced, which solved the problem of failing to effectively reduce the risk of MACE and achieved a significant reduction in the risk of cardiovascular events, especially 4P-MACE.
Patent Information
- Application Number
- CN202480015179.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-02-03
- Filing Date
- 2024-02-02
- Publication Date
- 2025-09-23
AI Technical Summary
Existing technologies have failed to effectively reduce the risk of major adverse cardiovascular events (MACE) in subjects who have not experienced major atherosclerotic cardiovascular disease (ASCVD) events, especially in subjects with high LDL-C levels who are at high risk of a first cardiovascular event.
Administration of RNAi agents containing specific nucleotide sequences, including antisense and sense strands, reduces PCSK9 protein levels through the RNA interference mechanism, thereby lowering LDL-C and subsequently reducing the risk of MACE.
Effectively reduced the risk of 4P-MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, or urgent coronary revascularization) in subjects who had not experienced ASCVD events, especially in subjects with high LDL-C, where the administration of RNAi agents significantly reduced LDL-C levels and prolonged the lowering effect.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to and the benefit of U.S. application No. 63 / 483,116, filed February 3, 2023, the contents of which are incorporated herein by reference in their entirety.
[0003] Sequence Listing
[0004] This application contains a sequence listing that has been electronically submitted in .XML format and is hereby incorporated by reference in its entirety. The .XML copy was created on February 1, 2024, is named PAT059477-WO-PCT_SL.xml, and is 25KB in size. Technical Field
[0005] The present invention relates to methods for reducing the risk of major adverse cardiovascular events (MACE) in a subject, and to RNAi agents and pharmaceutical compositions for use in such methods, the method comprising administering an RNAi agent. Provided herein are methods that are particularly effective in preventing cardiovascular death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, or urgent coronary revascularization (4P-MACE) in subjects who have not experienced a major atherosclerotic cardiovascular disease (ASCVD) event, particularly when the subject is at increased risk for a first MACE. Background Art
[0006] Despite significant improvements in recent decades, cardiovascular disease (CVD) remains the leading cause of death worldwide, killing more than 17 million people annually (WHO 2019). In 2019, an estimated 1,055,000 people in the United States (US) experienced a coronary event, including 720,000 new and 335,000 recurrent coronary events (Benjamin et al. 2019). These findings highlight the importance of preventing a first major ASCVD event in patients at high CV risk.
[0007] Long-term exposure to elevated low-density lipoprotein cholesterol (LDL-C) increases cumulative plaque burden and ASCVD risk, and lifelong exposure to higher LDL-C, especially long-term exposure to persistently elevated LDL-C, leads to acute coronary syndromes early in life and is a major risk factor for the development of ASCVD. Therefore, there is an unmet need to reduce the risk of major adverse cardiovascular events (MACE) in subjects, particularly in cases where the subject has not experienced a major ASCVD event (also known as primary prevention), such as in cases where the subject has not experienced a major ASCVD event in the approximately 12 months prior to administration of the RNAi agent described herein. Summary of the Invention
[0008] Therefore, the present invention addresses this need by providing a method for reducing the risk of major adverse cardiovascular events (MACE) in subjects who have not experienced a major atherosclerotic cardiovascular disease (ASCVD) event.
[0009] The MACE is cardiovascular death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, or urgent coronary revascularization.
[0010] Wherein the method comprises administering to the subject an interfering ribonucleic acid (RNAi) agent, wherein the RNAi agent comprises:
[0011] an antisense strand comprising the nucleotide sequence 5'-asCfsaAfAfAfgCfaAfaAfcAfgGfuCfuagsasa-3' (SEQ ID NO: 3), and
[0012] a sense strand comprising the nucleotide sequence 5'-csusagacCfuGfudTuugcuuuugu-3' (SEQ ID NO: 4),
[0013] wherein a, g, c, and u are 2'-O-methyl (2'-OMe) modified A, G, C, and U nucleotides, respectively; Af, Gf, Cf, and Uf are 2'-fluoro A, G, C, and U modified nucleotides, respectively; dT is a deoxythymidine nucleotide, and s is a phosphorothioate linkage; and
[0014] wherein the sense strand is conjugated to at least one ligand.
[0015] The present invention also provides RNAi agents for use in such methods, and pharmaceutical compositions comprising RNAi agents for use in such methods.
[0016] The invention also provides use of a RNAi agent in the manufacture of a medicament for use in the methods of the invention.
[0017] The present inventors have discovered that by administering an RNAi agent (e.g., inclisiran) to a subject as defined in the claims, the risk of 4P-MACE (first occurrence of CV death, non-fatal MI, non-fatal ischemic stroke, or urgent coronary revascularization) is reduced in high CV risk subjects with no prior major ASCVD events and LDL-C ≥ 70 mg / dL (1.81 mmol / L) but < 190 mg / dL (4.91 mmol / L), who were treated with the RNAi agent. These methods are particularly useful for reducing the risk of 4P-MACE in subjects at increased risk of a first MACE. The present inventors have also discovered that by administering an RNAi agent (e.g., inclisiran) to a subject as defined herein, the risk of 3P-MACE (CV death, non-fatal MI, or non-fatal ischemic stroke) or CV death is reduced in the same subject. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] The embodiments of the present invention will be described with reference to the following drawings, in which:
[0019] Figure 1 A summary of the screening algorithm is presented showing the screening strategy as used in Example 1.
[0020] Figure 2 is a diagram of the study design used in Example 1.
[0021] Figure 3 The assay procedures for the analysis of the primary and secondary endpoints in the trial according to Example 1 are presented. DETAILED DESCRIPTION
[0022] Treatment and prevention methods
[0023] Cardiovascular disease (including ASCVD) or death is attributed to potentially modifiable risk factors. Elevated LDL-C is the primary risk factor for ASCVD and contributes to the development of ASCVD in a subject. Atherosclerosis is a chronic, progressive disease. The accumulation of fatty and fibrous material in the innermost lining of the arteries leads to the formation of atherosclerotic plaques. ASCVD includes (1) coronary artery disease (ischemic heart disease); acute coronary syndromes (MI, unstable angina) and stable angina; (2) carotid and cerebral artery disease: ischemic stroke, transient ischemic attack (TIA); and (3) peripheral artery disease.
[0024] Long-term exposure to elevated LDL-C increases cumulative plaque burden and ASCVD risk, and lifelong exposure to higher LDL-C, especially long-term exposure to persistently elevated LDL-C, leads to acute coronary syndromes early in life and is a major risk factor for the development of ASCVD. Therefore, there is an unmet need for reducing the risk of MACE in subjects, particularly when the subject has not experienced a major ASCVD event or when the subject has not experienced a major ASCVD event in the approximately 12 months prior to administration of the RNAi agent. The present invention addresses this need.
[0025] In some embodiments, the subject's LDL-C levels are reduced after administration of the RNAi agent. As mentioned above, LDL-C is one of the most easily modifiable risk factors for ASCVD; however, despite widespread use of statins, four out of five patients do not achieve guideline-recommended LDL-C targets. PCSK9 inhibition provides an effective method for lowering LDL-C.
[0026] In one aspect, the present invention provides a method for reducing the risk of a major adverse cardiovascular event (MACE) in a subject who has not experienced a major atherosclerotic cardiovascular disease (ASCVD) event, comprising administering an interfering RNA (RNAi) agent to the subject. The present invention is based, at least in part, on the use of small interfering RNA (siRNA) molecules (a type of RNAi agent) as a means to reduce PCSK9 protein levels, which in turn reduces LDL-C levels. Through RNA interference, siRNA molecules bind to the RNA-induced silencing complex (RISC) within the cell, enabling it to cleave the messenger RNA (mRNA) encoding PCSK9. The cleaved mRNA is degraded and thus unavailable for protein translation, resulting in reduced PCSK9 protein levels, thereby reducing LDL-C levels. The inventors have discovered that administering an RNAi agent to reduce LDL-C levels in subjects who have not experienced a major ASCVD event is effective in reducing the risk of 4P-MACE in these subjects. 4P-MACE is defined as the composite of cardiovascular death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, or urgent coronary revascularization (i.e., a subject requiring urgent coronary revascularization, such as a subject with coronary artery disease (CAD)). As will be appreciated by those skilled in the art, in the context of the present invention, "combination" means the occurrence of any one of the specified component events.
[0027] Thus, the present invention provides a method of reducing the risk of a major adverse cardiovascular event (MACE) in a subject who has not experienced an ASCVD event, wherein the MACE is cardiovascular death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, or urgent coronary revascularization, wherein the method comprises administering to the subject an interfering ribonucleic acid (RNAi) agent as described herein.
[0028] Major adverse cardiovascular events (MACE)
[0029] As will be apparent to those skilled in the art, reducing the risk of an event, such as a major adverse cardiovascular event (MACE), in a subject can also be described as:
[0030] (a) Methods to prevent events (e.g., MACE) in subjects;
[0031] (b) methods for primary prevention of events (e.g., MACE) in subjects;
[0032] (c) methods to reduce the rate of events (e.g., MACE) in subjects; or
[0033] (d) Methods to delay the occurrence of an event (e.g., MACE) in the subject.
[0034] In all aspects of the invention, it will also be apparent to those skilled in the art that all references described herein to "reducing the risk of an event" may also be described as "preventing" such an event.
[0035] It will also be apparent to the skilled artisan that the reduction in risk of an event in a subject is typically assessed relative to a subject not administered the RNAi agent (eg, a subject receiving a placebo).
[0036] The method of the present invention comprises administering an RNAi agent to a subject, and the method is effective in reducing the risk of MACE in a subject who has not experienced a major atherosclerotic cardiovascular disease (ASCVD) event, compared to a subject who has not been administered the RNAi agent.
[0037] In some aspects, the risk of 4P-MACE is reduced. 4P-MACE is a composite of cardiovascular death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, or urgent coronary revascularization. Reducing the risk of 4P-MACE means reducing the risk of a subject experiencing any of these events.
[0038] The present invention also provides methods of reducing the risk of cardiovascular death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, or urgent coronary revascularization in a subject.
[0039] The present invention also provides methods for reducing the risk of other types of MACE in subjects who have not experienced a major atherosclerotic cardiovascular disease (ASCVD) event. For example, the inventors have found that by administering an RNAi agent (e.g., Inksiran) to a subject as defined herein, the risk of 3P-MACE (cardiovascular death, non-fatal myocardial infarction, or non-fatal ischemic stroke) or the risk of cardiovascular death is reduced.
[0040] The reduction in the risk of MACE in a subject can be quantified using the hazard ratio for MACE (e.g., 4P-MACE or 3P-MACE). The hazard ratio for MACE is the probability that a MACE will occur in the next time interval if it has not already occurred, divided by the length of that interval.
[0041] Reducing the risk of a subject experiencing MACE can also be quantified by determining the average time to MACE (e.g., 4P-MACE or 3P-MACE) in subjects administered an RNAi agent according to the methods of the present invention compared to the average time to MACE in subjects not administered the RNAi agent. For example, if the average time to MACE in subjects administered an RNAi agent according to the methods of the present invention is greater than the average time to MACE in subjects not administered the RNAi agent, then the risk of MACE is reduced.
[0042] In some embodiments, reducing the risk of MACE in subjects who have not experienced a major atherosclerotic cardiovascular disease (ASCVD) event (wherein MACE is cardiovascular death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, or urgent coronary revascularization) is defined as a reduction in the hazard rate in subjects who have been administered the RNAi agent compared to subjects who have not been administered the RNAi agent. In some embodiments, risk is defined as a reduction in the hazard rate by about 20% in subjects who have been administered the RNAi agent compared to subjects who have not been administered the RNAi agent.
[0043] Reduce the risk of other events
[0044] In other aspects that may be combined with any other aspect described herein, the present invention also provides methods for reducing the risk of an event as further described below in a subject who has not experienced a major atherosclerotic cardiovascular disease (ASCVD) event. These methods comprise administering to the subject a RNAi agent described herein, and effectively reducing the risk of such an event in a subject who has not experienced a major atherosclerotic cardiovascular disease (ASCVD) event compared to a subject who has not been administered the RNAi agent.
[0045] Exemplary events according to these aspects of the invention are described below. A skilled person can determine whether the risk of an event is reduced, for example, by determining the average time to first occurrence of the event in subjects to whom the RNAi agent of the invention has been administered, and comparing this to the average time to first occurrence of the event in comparable subjects to whom the RNAi agent has not been administered. These methods include administering to a subject an RNAi agent as described herein.
[0046] In some aspects, the invention provides methods of reducing the risk of CV events, such as first or recurrent nonfatal MI, nonfatal ischemic stroke, urgent revascularization, hospitalization for unstable angina, hospitalization for heart failure, or major adverse limb event (MALE).
[0047] In some aspects, the present invention provides methods of reducing the risk of urgent coronary revascularization.
[0048] In some aspects, the present invention provides methods of reducing the risk of all-cause mortality.
[0049] In some aspects, the invention provides methods of reducing the risk of CV death, non-fatal MI, non-fatal ischemic stroke, and urgent coronary revascularization (first or recurrent).
[0050] In some aspects, the invention provides methods for reducing the risk of CV death, non-fatal MI, and non-fatal ischemic stroke (first or recurrent).
[0051] In some aspects, the invention provides methods of reducing the risk of any coronary heart disease (CHD) event, eg, where the CHD event is death from CHD, non-fatal MI, unstable angina requiring hospitalization, or urgent coronary revascularization.
[0052] In some aspects, the present invention provides methods of reducing the risk of CV mortality.
[0053] In some aspects, the invention provides methods of reducing the risk of fatal or non-fatal MI.
[0054] In some aspects, the present invention provides methods of reducing the risk of fatal or non-fatal ischemic stroke.
[0055] In some aspects, the invention provides methods of reducing the risk of all-cause mortality, nonfatal MI, or nonfatal ischemic stroke.
[0056] In some aspects, the invention provides methods of reducing the risk of all-cause mortality, non-fatal MI, non-fatal ischemic stroke, or urgent coronary revascularization.
[0057] In some aspects, the present invention provides methods for reducing the risk of a major adverse limb event (MALE), for example, wherein the MALE is acute lower limb ischemia, lower limb amputation due to ischemia, or urgent lower limb revascularization due to ischemia.
[0058] In some aspects, the invention provides methods of reducing the risk of first or recurrent all-cause revascularization, eg, where the revascularization is coronary, carotid, or peripheral revascularization.
[0059] In some aspects, the invention provides methods for reducing the risk of a first or recurrent total coronary event, such as CHD death, MI, hospitalization for unstable angina, and / or urgent / elective revascularization.
[0060] In some aspects, the invention provides methods for reducing the risk of first or recurrent all-cause CV hospitalization, such as MI hospitalization and unstable angina hospitalization.
[0061] In some aspects, the present invention provides methods for reducing the risk of a first or recurrent venous thromboembolism leading to hospitalization or death.
[0062] In another aspect, the present invention provides a method for reducing the level of LDL-C and other lipid parameters in a subject compared to a baseline. For example, lipid parameters may include one or more of the following: total cholesterol, high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein cholesterol (VLDL-C), non-HDL-C, triglycerides, and lipoprotein (a) (Lp(a)). The reduction in the level of LDL-C or other lipid parameters in a subject can be determined by comparing the percentage change or absolute change in the level of LDL-C and other lipid parameters compared to a baseline at different time points, such as the time points shown in the assessment schedule (activity schedule) in Example 1 (e.g., V1, V2, V3, etc.).
[0063] In exemplary embodiments of all aspects of the invention, the risk of adverse events (AEs) or serious adverse events (SAEs) is lower in subjects who have been administered an RNAi agent. For example, if the incidence or total occurrence of AEs or SAEs in subjects who have been administered an RNAi agent of the invention is similar to or lower than the incidence or total occurrence of AEs or SAEs in subjects who have not been administered an RNAi agent (e.g., subjects who have been administered a placebo), then the risk of AEs or SAEs in subjects who have been administered an RNAi agent is lower.
[0064] Lowering LDL-C and PCSK9 levels
[0065] In some embodiments of the invention, the administration of the RNAi agent reduces LDL-C levels in a subject. In an exemplary embodiment, the administration of the RNAi agent reduces the LDL-C levels of the subject by greater than about 20%, or greater than about 25%, or greater than about 30%, or greater than about 35%, or greater than about 40%, or greater than about 45%, or greater than about 50%, or greater than about 55%, or greater than about 60%, compared to baseline LDL-C levels.
[0066] In some embodiments, the reduction in LDL-C levels following administration of the RNAi agent can be maintained for about 30 days or longer, 60 days or longer, 90 days or longer, 180 days or longer, 1 year or more, 2 years or more, 3 years or more, 4 years or more, 5 years or more, or 6 years or more.
[0067] In an exemplary embodiment, these reductions in LDL-C levels can be achieved by administering about 284 mg of Inxilane (equivalent to about 300 mg of Inxilane sodium), e.g., by subcutaneous injection, and wherein the method comprises:
[0068] (a) a loading phase, which consists of administering Inxilan in two doses separated by an interval of approximately 90 days (3 months), followed by
[0069] (b) A maintenance phase, which involves administering one or more doses of Inxilan, with each dose separated by an interval of approximately 180 days (6 months).
[0070] The time intervals may be varied to account for any missed doses, as further described below.
[0071] Administration of the RNAi agent also reduces the level of PCSK9 in the subject. In some embodiments, administration of the RNAi agent can reduce PCSK9 levels by greater than about 25%, or greater than about 30%, or greater than about 35%, or greater than about 40%, or greater than about 45%, or greater than about 50%, or greater than about 55%, or greater than about 60%, or greater than about 65%, or greater than about 70%, or greater than about 75%, or greater than about 80%, or greater than about 85%, or greater than about 90%, or greater than about 95%, compared to baseline PCSK9 levels or compared to PCSK9 levels before administration of the RNAi agent.
[0072] In some embodiments, the reduction in PCSK9 levels following administration of the RNAi agent can be maintained for about 30 days or longer, 60 days or longer, 90 days or longer, 180 days or longer, 1 year or more, 2 years or more, 3 years or more, 4 years or more, 5 years or more, or 6 years or more.
[0073] In an exemplary embodiment, these reductions in PCSK9 levels can be achieved by administering about 284 mg of Inxilane (equivalent to about 300 mg of Inxilane sodium), e.g., subcutaneously, and wherein the method comprises:
[0074] (a) a loading phase, which consists of administering Inxilan in two doses separated by an interval of approximately 90 days (3 months), followed by
[0075] (b) A maintenance phase, which involves administering one or more doses of Inxilan, with each dose separated by an interval of approximately 180 days (6 months).
[0076] Subjects for treatment
[0077] The methods of the present invention can be used to reduce the risk of MACE in subjects who have not experienced a major atherosclerotic cardiovascular disease (ASCVD) event.
[0078] Subjects at increased risk of first MACE
[0079] These methods are particularly useful for reducing the risk of MACE in subjects who are at increased risk of a first MACE.
[0080] Increased risk of first MACE was defined as any of the following:
[0081] a. Evidence of atherosclerotic CAD on CT or invasive coronary angiography, defined as stenosis of ≥ 20% but < 50% in the left main coronary artery or ≥ 20% but < 70% in any major epicardial coronary artery;
[0082] b. Coronary artery calcification (CAC) score obtained on CT scan ≥ 100 Agatston units;
[0083] c. High 10-year ASCVD risk ≥ 20% (assessed using the pooled cohort equation);
[0084] d. Intermediate 10-year ASCVD risk 7.5% to < 20% (estimated using the pooled cohort equation) and the presence of at least two of the following risk-enhancing factors:
[0085] i. First-degree relative with a history of premature ASCVD (male, age < 55 years; female, age < 65 years)
[0086] ii. History of premature menopause before the age of 40
[0087] iii. History of maternal pregnancy complications (defined as a history of preeclampsia, gestational hypertension, or gestational diabetes)
[0088] iv. South Asian descent
[0089] v. Chronic inflammatory disorder (defined as rheumatoid arthritis, systemic lupus erythematosus, psoriasis covering ≥ 10% of body surface area, Crohn's disease, ulcerative colitis, or HIV / AIDS)
[0090] vi. High-sensitivity C-reactive protein (hsCRP) ≥ 2 mg / L and the absence of any underlying acute or inflammatory condition (including any chronic inflammatory disorder listed in criterion dv above)
[0091] vii. Lipoprotein(a) ≥ 50 mg / dL or 125 nmol / L
[0092] viii. Estimated glomerular filtration rate (eGFR) < 60 mL / min / 1.73 m 2
[0093] ix. Ankle-brachial index (ABI) < 0.9 and no intermittent claudication symptoms; or
[0094] x. Metabolic syndrome.
[0095] A skilled artisan is able to determine whether a subject is at increased risk for a first MACE, as defined by the above criteria.
[0096] For example, Achenbach and Raggi (2010) reviewed exemplary methods for determining evidence of atherosclerotic CAD on CT or invasive coronary angiography and determining a CAC score obtained by CT scan.
[0097] The pooled cohort equations used to estimate ASCVD risk are explained in further detail below.
[0098] The diagnostic criteria for metabolic syndrome are explained in further detail below.
[0099] The levels of high-sensitivity C-reactive protein (hsCRP), lipoprotein(a), estimated glomerular filtration rate (eGFR), and LDL-C in a subject can be determined by a skilled artisan using conventional tests, such as commercially available immunoassays or commercially available tests (e.g., lipid panels) to measure the levels of these substances in a subject (e.g., in serum obtained from a subject).
[0100] The skilled person can also calculate the subject's ankle-brachial index (ABI), for example, by measuring blood pressure in the subject's ankle and brachial artery.
[0101] In some embodiments, the subject has not experienced MACE at any time prior to administration of the RNAi agent.
[0102] In some embodiments, the subject has an LDL-C level of ≥ 70 mg / dL (≥ 1.81 mmol / L) but < 190 mg / dL (< 4.91 mmol / L).
[0103] In some embodiments, the subject is a mammal, such as a primate. In preferred embodiments of all aspects of the invention, the subject is a human. In some embodiments, the subject is referred to as a patient.
[0104] In some embodiments, the subject is an adult (eg, an adult), eg, greater than or equal to 40 years old, and optionally less than 80 years old.
[0105] Background lipid-lowering therapy, additional PCSK9-targeted therapy, and other therapies
[0106] In some embodiments, the subject is or has been treated with background lipid-lowering therapy (LLT). In other embodiments, the subject is not or has not been treated with background lipid-lowering therapy (LLT). As described herein, during administration of the RNAi agent to the subject, the subject may remain on background LLT. Background LLT may be a statin and / or ezetimibe. Background statin LLT may be moderate or high intensity.
[0107] In some embodiments, the subject has not been treated with an additional PCSK9-targeted therapy prior to administration of the RNAi agent. In other embodiments, the subject has been treated with an additional PCSK9-targeted therapy prior to administration of the RNAi agent. Exemplary additional PCSK9-targeted therapies include PCSK9-blocking monoclonal antibodies (mAbs) that lower LDL-C levels, such as alirocumab or evolocumab, and thereby lower LDL-C levels.
[0108] The RNAi agent (eg, Inksilan) can be administered immediately after the last dose of the monoclonal antibody PCSK9 inhibitor. Preferably, the RNAi agent (eg, Inksilan) is administered within 2 weeks after the last dose of the monoclonal antibody PCSK9 inhibitor.
[0109] In some embodiments, the subject has not been treated with lomitapide and / or mipometapide.
[0110] Aggregate queue equation
[0111] The 2013 ACC / AHA CV risk guidelines introduced the Pooled Cohort Equation (PCE) as a sex- and race-specific tool for estimating the absolute 10-year incidence of ASCVD events in a primary prevention population (Goff et al. 2014). These equations are derived from extensive data from several large, ethnically and geographically diverse, modern NHLBI-sponsored cohort studies, including the ARIC (Atherosclerosis Risk in Communities) study, the Cardiovascular Health Study, and the CARDIA (Coronary Artery Risk Development in Young Adults) study, combined with applicable data from the Framingham Original and Offspring Study cohorts. Risk estimates are based on a combination of established CV risk factors prospectively examined in the specific cohorts selected for PCE derivation. If indicated, an ASCVD risk score is calculated for the eCRF using the PCE equations for inclusion criteria assessment.
[0112] The variables included in PCE are:
[0113] • Current age
[0114] • Gender (male, female)
[0115] • Race (White, African American, Other)
[0116] •Smoking status (current, former, never)
[0117] • Systolic blood pressure (mmHg)
[0118] • Hypertension treatment status (yes, no)
[0119] • History of diabetes (yes, no)
[0120] • Total cholesterol and HDL cholesterol levels (in mg / dL or mmol / L)
[0121] For more information on the ASCVD Risk Tool, see Lloyd-Jones et al., 2018. This tool estimates 10-year ASCVD risk in adults aged 40–79 years.
[0122] Clinical diagnostic criteria for metabolic syndrome
[0123] Metabolic syndrome is a risk-enhancing factor for ASCVD. Metabolic syndrome is diagnosed when any three of the following five risk factors are present:
[0124] Risk factors supporting a diagnosis of metabolic syndrome
[0125]
[0126] Adapted from: Grundy et al. 2019 (Table S2 in the Web Supplement) and Grundy et al. 2004
[0127] These risk factors can be measured or determined in a subject by methods known to those skilled in the art.
[0128] Primary prevention
[0129] As described above, the methods of the present invention can be used to reduce the risk of MACE in subjects who have not experienced a major atherosclerotic cardiovascular disease (ASCVD) event. This is also referred to by those skilled in the art as "primary prevention."
[0130] A major ASCVD event can be defined as any of the following:
[0131] a. Acute coronary syndrome (ACS) at any time before administration of the RNAi agent, eg, ACS within about 12 months before administration of the RNAi agent;
[0132] b. myocardial infarction at any time before administration of the RNAi agent;
[0133] c. ischemic stroke at any time before administration of the RNAi agent; or
[0134] d. Symptomatic peripheral arterial disease (PAD) at any time prior to administration of the RNAi agent, such as evidenced by intermittent claudication, prior revascularization, or amputation due to atherosclerotic disease.
[0135] In an exemplary embodiment, the subject has not experienced major ASCVD in the approximately 12 months prior to administration of the RNAi agent.
[0136] Additional factors may indicate that a subject is not suitable for the methods of the present invention. The following examples define subjects that are particularly suitable for the methods of the present invention with reference to these factors.
[0137] In some embodiments, the subject has no history of ischemia-driven revascularization in the coronary or extracoronary arterial bed prior to administration of the RNAi agent.
[0138] In some embodiments, the subject is free of coronary atherosclerosis on CT angiography or invasive coronary angiography within 2 years prior to administration of the RNAi agent.
[0139] In some embodiments, the subject does not achieve a coronary artery calcification (CAC) score of 0 within 2 years prior to administration of the RNAi agent.
[0140] In some embodiments, the subject does not have active liver disease or liver dysfunction, eg, identified as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than or equal to 3 times the upper limit of normal (ULN).
[0141] Subgroups of subjects
[0142] The methods of the present invention may be particularly suitable or effective for certain subgroups of subjects.
[0143] In some embodiments, the subject may have ASCVD, ASCVD equivalent risk, increased cardiovascular disease (CVD) risk, heterozygous familial hypercholesterolemia, or homozygous familial hypercholesterolemia, require lowering of low-density lipoprotein cholesterol (LDL-C), or otherwise have a disease that would benefit from lowering of LDL-C, or a combination thereof.
[0144] In certain embodiments, a subject may be "ASCVD equivalent risk" if they have one or more of the following: symptomatic atherosclerosis, type 2 diabetes, familial hypercholesterolemia, including subjects with a 10-year cardiovascular event risk assessed by the Fleming risk score (score > 20%) or equivalent and a target LDL-C < 100 mg / dl. In some embodiments, a subject may have heterozygous familial hypercholesterolemia (HeFH).
[0145] The Fleming risk score is a method well known to the skilled person for estimating 1-year cardiovascular disease risk that takes into account factors such as age, HDL-C level, total cholesterol level, systolic blood pressure, and history of smoking and diabetes, and is further described in D'agostino et al. 2008.
[0146] Pooled cohort equations can also be used to estimate ASCVD risk.
[0147] In some embodiments, the subject can be less than 65 years old, 65 to 74 years old, or at least 75 years old. The subject can be male or female.
[0148] In some embodiments, the subject has less than 30, 30 to less than 35, or at least 35 kg / m 2 Baseline body mass index (BMI).
[0149] In some embodiments, the subject has or has had diabetes.
[0150] In some embodiments, the subject is a current or former smoker.
[0151] In some embodiments, the subject has or has had hypertension.
[0152] In some embodiments, the subject has a baseline LDL-C level of less than 100 mg / dL, or at least 100 mg / dL.
[0153] In some embodiments, the subject has a baseline triglyceride level of less than 150, 150 to less than 200, or at least 200 mg / dL.
[0154] In some embodiments, the subject has a baseline high-sensitivity C-reactive protein (hs-CRP) level of less than 2 or at least 2 mg / dL.
[0155] In some embodiments, the subject is being treated with a high-intensity or moderate-intensity statin at baseline, or is not being treated with a statin.
[0156] In some embodiments, the subject is at risk for cardiac health issues, which may include: having an acute coronary syndrome; having a history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease of atherosclerotic origin; being male; having a family history of heart disease, ASCVD, or ASCVD equivalent risk; being a smoker; being physically inactive; having high blood pressure; having high blood cholesterol; having diabetes or prediabetes; being overweight or obese; having a history of preeclampsia during pregnancy; having uncontrolled stress and / or anger; being postmenopausal; having an unhealthy diet, such as a diet high in salt, saturated fat, trans fat, cholesterol, and / or refined sugar; being 55 years of age or older; having sleep apnea; having anemia; or a combination thereof. Thus, the method can be targeted to, for example, a young subject with a family history of heart disease, or a subject who smokes but does not have high blood pressure.
[0157] Other interventions
[0158] The subject being treated in the methods of the present invention can be treated with background LLT throughout the duration of the RNAi agent administration. Additionally, the subject can be provided with additional risk-based cardiovascular disease (CVD) preventive interventions, such as education on healthy eating, exercise, and weight control or other lifestyle changes. The subject may be receiving maximally tolerated statin therapy. Maximum doses of statins are known in the art.
[0159] Such healthy diets are known in the art, such as diets designed to improve lipid levels. For example, a diet designed to improve blood lipid levels may include eating lean meats; removing fat from meats; not eating fried foods or high-fat sauces; not eating egg yolks; using low-fat dairy products, such as skim milk or 1% milk, low-fat frozen yogurt, low-fat ice cream, and low-fat cheese; and eating foods that are sources of fiber, such as fruits and vegetables.
[0160] Subjects may require additional lowering of LDL-C levels.
[0161] RNAi agents
[0162] The RNAi agent used in the method of the present invention is a double-stranded RNAi agent. The RNAi agent can inhibit the expression of proprotein convertase subtilisin kexin 9 (PCSK9) in cells.
[0163] In some aspects of the invention, the RNAi agent is a double-stranded ribonucleic acid comprising a sense strand and an antisense strand forming a double-stranded region, wherein the antisense strand comprises the nucleotide sequence of SEQ ID NO: 1 and the sense strand comprises the nucleotide sequence of SEQ ID NO: 2. In some embodiments, the antisense strand comprises the nucleotide sequence of SEQ ID NO: 3 and the sense strand comprises the nucleotide sequence of SEQ ID NO: 4.
[0164] In some aspects of the invention, the RNAi agent comprises:
[0165] an antisense strand comprising the nucleotide sequence 5'-asCfsaAfAfAfgCfaAfaAfcAfgGfuCfuagsasa-3' (SEQ ID NO: 3), and
[0166] a sense strand comprising the nucleotide sequence 5'-csusagacCfuGfudTuugcuuuugu-3' (SEQ ID NO: 4),
[0167] wherein a, g, c, and u are 2'-O-methyl (2'-OMe) modified A, G, C, and U nucleotides, respectively; Af, Gf, Cf, and Uf are 2'-fluoro A, G, C, and U modified nucleotides, respectively; dT is a deoxythymidine nucleotide, and s is a phosphorothioate linkage; and wherein the sense strand is conjugated to at least one ligand.
[0168] In some aspects of the invention, the RNAi agent comprises:
[0169] an antisense strand consisting of the nucleotide sequence 5'-asCfsaAfAfAfgCfaAfaAfcAfgGfuCfuagsasa-3' (SEQ ID NO: 3), and
[0170] The sense strand consists of the nucleotide sequence 5'-csusagacCfuGfudTuugcuuuugu-3' (SEQ ID NO: 4),
[0171] wherein a, g, c, and u are 2'-O-methyl (2'-OMe) modified A, G, C, and U nucleotides, respectively; Af, Gf, Cf, and Uf are 2'-fluoro A, G, C, and U modified nucleotides, respectively; dT is a deoxythymidine nucleotide, and s is a phosphorothioate linkage; and wherein the sense strand is conjugated to at least one ligand.
[0172] In some embodiments, the ligand comprises the structure:
[0173] .
[0174] This structure represents triantennary N-acetylgalactosamine (GalNAc), which facilitates the uptake of RNAi agents by hepatocytes. Within hepatocytes, the RNAi agent utilizes the RNA interference mechanism and directs the catalytic degradation of PCSK9 mRNA. This increases the recruitment and expression of LDL-C receptors on the hepatocyte surface, thereby increasing LDL-C uptake and lowering circulating LDL-C levels.
[0175] In a further embodiment, the ligand is conjugated to the 3' end of the sense strand.
[0176] The RNAi agent can be conjugated to a ligand as shown in the following scheme:
[0177]
[0178] wherein X is O or S. In a preferred embodiment, X is O.
[0179] Preferably, the RNAi agent is Inksilan. Inksilan is a preferred RNAi agent for all aspects of the present invention. Inksilan is a double-stranded RNAi agent that is a small interfering RNA (siRNA) directed against PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA. As described above, Inksilan is conjugated to triantennary N-acetylgalactosamine (GalNAc) at the 3' end of the sense strand to promote hepatocyte uptake. With one exception, the 2' ribose moiety of Inksilan is present as a 2'-F or 2'-OMe ribonucleotide. In addition, the six terminal phosphodiester backbones are present as phosphorothioate linkages, as shown below.
[0180] Inxilan is described in WHO Drug Information, Volume 30, Issue 3, 2016, Recommendations INN: List 76, pages 504-506, which is incorporated herein by reference.
[0181] The chemical name of Inksilan is:
[0182] The following duplex: [(2S,4R)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-yl}-4-hydroxypyrrolidin-2-yl]methylhydrogen
[0183] All-P-ambo-2'-O-methyl-P-thiocytidylyl-
[0184] (3'→5')-2'-O-methyl-P-thiouridinylated-
[0185] (3'→5')-2'-O-methyladenyl-
[0186] (3'→5')-2'-O-methylguanylate-
[0187] (3'→5')-2'-O-methyladenyl-
[0188] (3'→5')-2'-O-methylcytidine-
[0189] (3'→5')-2'-deoxy-2'-fluorocytidylyl-
[0190] (3'→5')-2'-O-methyluridine-
[0191] (3'→5')-2'-deoxy-2'-fluoroguanylate-
[0192] (3'→5')-2'-O-methyluridine-
[0193] (3'→5')-thymidyloyl-
[0194] (3'→5')-2'-O-methyluridine-
[0195] (3'→5')-2'-O-methyluridine-
[0196] (3'→5')-2'-O-methylguanylate-
[0197] (3'→5')-2'-O-methylcytidine-
[0198] (3'→5')-2'-O-methyluridine-
[0199] (3'→5')-2'-O-methyluridine-
[0200] (3'→5')-2'-O-methyluridine-
[0201] (3'→5')-2'-O-methyluridine-
[0202] (3'→5')-2'-O-methylguanylate-
[0203] (3'→5')-2'-O-methyl-3'-uridine ester
[0204] as well as
[0205] All-P-ambo-2'-O-methyl-P-thioadenylyl-
[0206] (5'→3')-2'-O-methyl-P-thioadenylyl-
[0207] (5'→3')-2'-O-methylguanylate-
[0208] (5'→3')-2'-O-methyladenyl-
[0209] (5'→3')-2'-O-methyluridine-
[0210] (5'→3')-2'-deoxy-2'-fluorocytidylyl-
[0211] (5'→3')-2'-O-methyluridine-
[0212] (5'→3')-2'-deoxy-2'-fluoroguanylate-
[0213] (5'→3')-2'-O-methylguanylate-
[0214] (5'→3')-2'-deoxy-2'-fluoroadenylyl-
[0215] (5'→3')-2'-O-methylcytidine-
[0216] (5'→3')-2'-deoxy-2'-fluoroadenylyl-
[0217] (5'→3')-2'-O-methyladenyl-
[0218] (5'→3')-2'-deoxy-2'-fluoroadenylyl-
[0219] (5'→3')-2'-O-methyladenyl-
[0220] (5'→3')-2'-deoxy-2'-fluorocytidylyl-
[0221] (5'→3')-2'-O-methylguanylate-
[0222] (5'→3')-2'-deoxy-2'-fluoroadenylyl-
[0223] (5'→3')-2'-deoxy-2'-fluoroadenylyl-
[0224] (5'→3')-2'-deoxy-2'-fluoroadenylyl-
[0225] (5'→3')-2'-O-methyl-P-thioadenylyl-
[0226] (5'→3')-2'-deoxy-2'-fluoro-P-thiocytidylyl-
[0227] (5'→3')-2'-O-methyladenosine.
[0228] In Inksilane chemical names (as shown above), the notation (3'→5') or (5'→3') refers to the direction of the internucleoside linkages (i.e., the direction of each interconnecting phosphate linkage, e.g., phosphodiester or phosphorothioate), which is the IUPAC convention for nucleic acids, and not to the termini of the chain having a third or fifth carbon in the sugar ring at its termini (e.g., antisense or sense strand).
[0229] The molecular formula of Inksilan is C 529 H 707 F 12 N 176 O 316 P 43 S6.
[0230] The structure of Inksilan is shown in the figure below:
[0231]
[0232] The following figure is another representation of the Inxilan structure:
[0233]
[0234] Abbreviations: Af = adenine 2'-F ribonucleotide; Cf = cytosine 2'-F ribonucleotide; Gf = guanine 2'-F ribonucleotide; Am = adenine 2'-OMe ribonucleotide; Cm = cytosine 2'-OMe ribonucleotide; Gm = guanine 2'-OMe ribonucleotide; Um = uracil 2'-OMe ribonucleotide; s is a phosphorothioate linkage.
[0235] Pharmaceutical compositions and administration
[0236] Salt form
[0237] Each dose of the administered RNAi agent can comprise the RNAi agent in salt form.
[0238] As used herein, the term "salt" or "salts" refers to acid addition salts or base addition salts of the RNAi agents described herein. "Salts" specifically include "pharmaceutically acceptable salts". The term "pharmaceutically acceptable salts" refers to salts that retain the biological effectiveness and properties of the RNAi agents described herein, and these salts are typically not biologically or otherwise undesirable. In many cases, the RNAi agents described herein are able to form base salts by virtue of the presence of acidic protons (e.g., acidic protons found in carboxylic acid or phosphate or other groups similar thereto).
[0239] Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
[0240] Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table. In certain embodiments, salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium, and magnesium salts.
[0241] Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, choline salts, diethanolamine, diethylamine, lysine, meglumine, piperazine, and tromethamine.
[0242] In another aspect, the RNAi agents described herein are in the form of sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, copper, isopropylamine, benzathine, choline salt, diethanolamine, diethylamine, lysine, meglumine, piperazine, or tromethamine salts.
[0243] In some embodiments, the RNAi agent is present in the dose to be administered in the form of a salt, such as a sodium salt or a potassium salt. Sodium salts are the preferred salt form of the RNAi agent, but other pharmaceutically acceptable salts, such as potassium salts or ammonium salts, may also be used. Preferably, the RNAi agent is an inxylane salt (e.g., inxylane sodium, inxylane potassium, or inxylane ammonium). More preferably, the RNAi agent is inxylane sodium (also known as inxylane sodium salt), but other pharmaceutically acceptable salts may also be used.
[0244] The molecular formula of sodium inxylane is C 529 H 664 F 12 N 176 Na 43 O 316 P 43S6 has a molecular weight of 17,284.72 g / mol. Its structural formula is as follows:
[0245]
[0246] Abbreviations: Af = adenine 2'-F ribonucleotide; Cf = cytosine 2'-F ribonucleotide; Gf = guanine 2'-F ribonucleotide; Am = adenine 2'-OMe ribonucleotide; Cm = cytosine 2'-OMe ribonucleotide; Gm = guanine 2'-OMe ribonucleotide; Um = uracil 2'-OMe ribonucleotide; s is a phosphorothioate linkage.
[0247] RNAi agents used and pharmaceutical compositions used
[0248] The present invention also provides RNAi agents for use in any of the methods of the present invention. Pharmaceutical compositions comprising RNAi agents for use in any of the methods of the present invention are also provided.
[0249] In addition to the RNAi agent or its salt, these pharmaceutical compositions may also include pharmaceutically acceptable excipients, carriers, buffers, stabilizers or other materials well known to those skilled in the art. Such materials are non-toxic and do not interfere with the efficacy of the RNAi agent. In a preferred embodiment, the pharmaceutical composition used comprises water for injection. In a further preferred embodiment, the pharmaceutical composition used comprises water for injection, and sodium hydroxide and / or phosphoric acid.
[0250] Dosage and dosage regimen
[0251] dose
[0252] The method of the present invention includes administering one or more dosages of RNAi agents. The RNAi agent can be provided in a therapeutically effective amount or a prophylactic effective amount. In all aspects of the present invention, those skilled in the art will recognize that the administration of the RNAi agent can include administering a therapeutically effective amount or a prophylactic effective amount of the RNAi agent to the subject in each dosage.
[0253] Reference to a "therapeutically effective amount" or a "prophylactically effective amount" refers to administering an appropriate amount of the RNAi agent according to the methods of the present invention to achieve the effect of reducing the risk of a major adverse cardiovascular event (MACE) in a subject who has not experienced a major atherosclerotic cardiovascular disease (ASCVD) event. It will also be apparent to those of skill in the art that the term "therapeutically effective amount" or "prophylactically effective amount" can refer to the following effect: reducing the risk of an event as described in other aspects of the invention described herein, such as reducing the risk of a first or recurrent non-fatal MI, non-fatal ischemic stroke, urgent revascularization, hospitalization for unstable angina, hospitalization for heart failure, or major adverse limb event (MALE), in a subject who has not experienced a major atherosclerotic cardiovascular disease (ASCVD) event.
[0254] Each dose administered to a subject may contain between about 100 mg and about 500 mg of an inxilamine salt. In some embodiments, each dose administered to a subject contains about 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg of an inxilamine salt. Preferably, the inxilamine salt is sodium inxilamine.
[0255] Each dose administered to a subject can contain between about 94 mg and about 473 mg of inxilane. In specific embodiments, each dose administered to a subject contains about 95 mg of inxilane (equivalent to about 100 mg of inxilane sodium), 189 mg of inxilane (equivalent to about 200 mg of inxilane sodium), 284 mg of inxilane (equivalent to about 300 mg of inxilane sodium), 388 mg of inxilane (equivalent to about 400 mg of inxilane sodium), or about 473 mg of inxilane (equivalent to about 500 mg of inxilane sodium). Inxilane can be included in these doses in the form of other salts, such as those described above, in an equivalent amount to the inxilane salt.
[0256] In some embodiments, each dose administered to a subject comprises about 284 mg of inxilane (or an equivalent amount of an inxilane salt). Preferably, each dose comprises about 284 mg of inxilane (equivalent to about 300 mg of inxilane sodium). This amount of inxilane is considered an exemplary therapeutically effective amount or an exemplary prophylactically effective amount.
[0257] In a preferred embodiment, a dose of about 284 mg of Inxilan (equivalent to about 300 mg of Inxilan sodium) is administered initially as a single subcutaneous injection, again at 3 months, and then every 6 months thereafter.
[0258] Loading phase and maintenance phase
[0259] In some embodiments, administration of the RNAi agent comprises a loading phase followed by a maintenance phase.
[0260] The loading phase may comprise administering one or more doses of the RNAi agent, for example administering at least two doses of the RNAi agent, each dose separated by a certain time interval. Preferably, the loading phase comprises administering the RNAi agent in two doses separated by a certain time interval.
[0261] The administration of each dose during the loading phase can be separated by a time interval of about 30 days (1 month) to 270 days (9 months). In some embodiments, the administration of each dose during the loading phase can be separated by a time interval of about 90 days (3 months) to 180 days (6 months). For example, the administration of each dose during the loading phase is separated by a time interval of about 30 days (1 month), about 60 days (2 months), about 90 days (3 months), about 120 days (4 months), about 150 days (5 months), or about 180 days (6 months). Preferably, the administration of each dose during the loading phase is separated by a time interval of about 90 days (3 months).
[0262] In some embodiments, administration during the maintenance phase comprises administering the RNAi agent in one or more doses, with each dose separated by a time interval. In an exemplary embodiment, the time interval between each dose administration is about 90 days (3 months) to about 270 days (9 months). Preferably, the time interval is about 180 days (6 months). In a further preferred embodiment, the time interval between each dose administration during the maintenance phase is of approximately equal duration—for example, the time interval between the first and second doses during the maintenance phase can be about 180 days (6 months), and the time interval between the second and third doses during the maintenance phase can be about 180 days (6 months).
[0263] In some embodiments, the interval between each dose administration is about 90 days (3 months) to about 270 days (9 months). For example, the interval can be between each dose administration during the maintenance phase, or between two separate doses from the loading phase and the maintenance phase, respectively. In some embodiments, the first dose of the maintenance phase is administered about 180 days (6 months) after the last dose of the loading phase.
[0264] The duration of the maintenance phase can be at least 1 year. Preferably, the duration of the maintenance phase is at least 2 years, at least 3 years, at least 4 years, at least 5 years, or at least 6 years. Due to the effective and sustained reduction in the subject's LDL-C level, the methods of the present invention are particularly useful in reducing the risk of MACE in subjects who have not experienced a major atherosclerotic cardiovascular disease (ASCVD) event when the RNAi agent is administered during a long-term maintenance phase (e.g., at least 4 years, at least 5 years, or at least 6 years). The ORION-3 open-label extension trial showed that over 4 years of treatment, initial administration of 284 mg of Inksilan in the form of 300 mg of Inksilan sodium to subjects, followed by administration at 3 months and then every 6 months, effectively and sustainably reduced the subjects' low-density lipoprotein cholesterol (LDL-C). LDL-C levels continued to decline during the four-year study period: from baseline (Day 1 of ORION-1) to Day 210, participants treated with Inxilan experienced an average LDL-C reduction of 47.5% (95% CI: -50.69, -44.27), and with twice-yearly dosing over four years, the average LDL-C reduction was 44.2%.
[0265] Thus, the subject may be initially administered an RNAi agent, administered again at 3 months, and then administered every 6 months. In some embodiments, administration of the RNAi agent comprises:
[0266] (a) a loading phase, consisting of two doses of the RNAi agent administered approximately 90 days (3 months) apart, followed by
[0267] (b) A maintenance phase, comprising administration of one or more doses of the RNAi agent, with each dose separated by an interval of approximately 180 days (6 months).
[0268] The time intervals may be varied to account for any missed doses, as further described below.
[0269] missed dose
[0270] In the methods of the present invention, the time point at which the RNAi agent is intended or expected to be administered according to a specific (original) dosing schedule (eg, initially, again 3 months, then every 6 months) is also referred to as the planned dose.
[0271] If the time to any scheduled dose is less than 90 days (3 months), the missed scheduled dose of the RNAi agent is administered immediately. In this case, the next dose of the RNAi agent is usually administered according to the original dosing schedule.
[0272] If any scheduled dose is missed for more than 90 days (3 months), the dosing regimen is restarted by administering the RNAi agent in a new loading phase consisting of a first dose and a second dose approximately 90 days (3 months) after the first dose, followed by a maintenance phase consisting of a dose administered approximately every 180 days (6 months) (i.e., the first dose of the maintenance phase is administered approximately 180 days (6 months) after the second dose of the loading phase).
[0273] Route of administration
[0274] In view of the mechanism of action of the RNAi agent of the present invention, subcutaneous administration of the RNAi agent is particularly suitable. Preferably, the RNAi agent is administered subcutaneously (sc), preferably by injection into the abdomen, upper arm or thigh. Particularly preferably, administration is performed by subcutaneous injection into the abdomen.
[0275] RNAi agents for subcutaneous administration can be included in pharmaceutical compositions.Pharmaceutical compositions can be formulated based on delivery modes readily achieved by those skilled in the art.
[0276] The RNAi agent can be administered in a sterile aqueous solution of about 1.5 mL volume. Preferably, the sterile aqueous solution has a pH of about 7.0. The sterile aqueous solution may contain sodium hydroxide and / or phosphoric acid to adjust the pH to a target pH of about 7.0. The sterile aqueous solution containing the RNAi agent is typically contained in a prefilled syringe for subcutaneous administration. The RNAi agent can be present in the water for injection in the pharmaceutical composition.
[0277] RNAi agents can also be administered intravenously (iv). In some embodiments, the RNAi agent is administered to the subject subcutaneously and intravenously, for example, one dose of the RNAi agent is administered subcutaneously and another dose of the RNAi agent is administered intravenously. Those skilled in the art are able to prepare suitable aqueous solutions for subcutaneous and / or intravenous administration (for example, the RNAi agent can be contained in a sterile aqueous solution at about pH 7.0) and administer the RNAi agent subcutaneously and / or intravenously. Examples of conventional techniques and protocols can be found in: Remington: The Science and Practice of Pharmacy, 23rd edition, 2020.
[0278] In specific embodiments where the RNAi agent is administered intravenously, each dose administered to a subject may comprise between about 100 mg and about 500 mg of an inxelane salt. In some embodiments, each dose administered to a subject comprises about 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg of an inxelane salt. Preferably, the inxelane salt is inxelane sodium. Each dose administered to a subject may comprise between about 94 mg and about 473 mg of inxelane. In specific embodiments, each dose administered to a subject comprises about 95 mg of inxelane (equivalent to about 100 mg of inxelane sodium), 189 mg of inxelane (equivalent to about 200 mg of inxelane sodium), 284 mg of inxelane (equivalent to about 300 mg of inxelane sodium), 388 mg of inxelane (equivalent to about 400 mg of inxelane sodium), or about 473 mg of inxelane (equivalent to about 500 mg of inxelane sodium). Inksilan may be included in these dosages in the form of other salts, such as those listed above, in equal amounts to the inksilan salt.
[0279] In specific embodiments where the RNAi agent is administered intravenously, each dose administered to the subject comprises approximately 284 mg of inxilane (or an equivalent amount of an inxilane salt). Preferably, each dose comprises approximately 284 mg of inxilane (equivalent to approximately 300 mg of inxilane sodium). In some embodiments, the method comprises administering the RNAi agent intravenously during the loading phase and subcutaneously during the maintenance phase. In other embodiments, the method comprises administering the RNAi agent intravenously for the first dose during the loading phase, administering the RNAi agent subcutaneously for each subsequent dose during the loading phase, and administering the RNAi agent subcutaneously for each dose during the maintenance phase.
[0280] In another embodiment, the method comprises administering the RNAi agent intravenously for the first dose of the loading phase and administering the RNAi agent subcutaneously for each subsequent dose. In embodiments where the method comprises administering the RNAi agent intravenously for the first dose of the loading phase and administering the RNAi agent subcutaneously for each subsequent dose, each dose in the loading phase can be separated by a time interval of about 30 days (1 month) to 270 days (9 months). In some of these embodiments, the administration of each dose in the loading phase can be separated by a time interval of about 90 days (3 months) to 180 days (6 months). For example, each dose in the loading phase is separated by a time interval of about 30 days (1 month), about 60 days (2 months), about 90 days (3 months), about 120 days (4 months), about 150 days (5 months), or about 180 days (6 months). Preferably, each dose in the loading phase is separated by a time interval of about 90 days (3 months).
[0281] RNAi agents can be administered in an outpatient setting. RNAi agents are typically administered by a healthcare professional.
[0282] Exemplary embodiments
[0283] The present invention provides the following exemplary embodiments:
[0284] Example 1. A method of reducing the risk of a major adverse cardiovascular event (MACE) in a subject who has not experienced a major atherosclerotic cardiovascular disease (ASCVD) event.
[0285] The MACE is cardiovascular death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, or urgent coronary revascularization.
[0286] Wherein the method comprises subcutaneously administering Inxilan to the subject, and the administering comprises:
[0287] (a) a loading phase, which consists of administering Inxilan in two doses separated by an interval of approximately 90 days (3 months), followed by
[0288] (b) a maintenance phase, which comprises administering one or more doses of Inxilan, wherein each dose is separated by an interval of approximately 180 days (6 months), and
[0289] Each dose contains approximately 284 mg of inxilamide (equivalent to approximately 300 mg of inxilamide sodium).
[0290] Example 2. A method of reducing the risk of a major adverse cardiovascular event (MACE) in a subject who has not experienced a major atherosclerotic cardiovascular disease (ASCVD) event.
[0291] The MACE is cardiovascular death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke, or urgent coronary revascularization.
[0292] A major ASCVD event is defined as any of the following:
[0293] a. Acute coronary syndrome (ACS) at any time before administration of the RNAi agent, eg, ACS within about 12 months before administration of the RNAi agent;
[0294] b. myocardial infarction at any time before administration of the RNAi agent;
[0295] c. ischemic stroke at any time before administration of the RNAi agent; or
[0296] d. symptomatic peripheral arterial disease (PAD) at any time prior to administration of the RNAi agent, as evidenced by intermittent claudication, prior revascularization, or amputation due to atherosclerotic disease,
[0297] Wherein the method comprises subcutaneously administering Inxilan to the subject, and the administering comprises:
[0298] (a) a loading phase, which consists of administering Inxilan in two doses separated by an interval of approximately 90 days (3 months), followed by
[0299] (b) a maintenance phase, which comprises administering one or more doses of Inxilan, wherein each dose is separated by an interval of approximately 180 days (6 months), and
[0300] Each dose contains approximately 284 mg of inxilamide (equivalent to approximately 300 mg of inxilamide sodium).
[0301] Overview
[0302] The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, immunology and pharmacology, known to those skilled in the art.
[0303] The term "comprising" encompasses "including" as well as "consisting of, eg, a composition "comprising" X may consist only of X or may include additional substances, eg, X + Y.
[0304] The term "about" in connection with a value x is optional and means, for example, x ± 10%, unless otherwise stated.
[0305] The term "baseline" can refer to the untreated condition, such as before the first administration or initiation of treatment.
[0306] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0307] Unless otherwise specified or obvious from the context, as used herein, the term "or" should be understood as inclusive and encompasses "or" as well as "and". All technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs and commonly used in the art to which this application belongs. The publications and other reference materials cited herein to describe the background of the invention and to provide additional details regarding its practice are incorporated herein by reference.
[0308] Examples
[0309] The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.
[0310] Example 1. Trial evaluating the efficacy of Inxilan in preventing major adverse cardiovascular events in high-risk primary prevention patients
[0311] A randomized, double-blind, placebo-controlled, multicenter study will be conducted to evaluate the efficacy of Inxilan in preventing major adverse cardiovascular events in high-risk primary prevention patients.
[0312] This is a phase III study designed to test the hypothesis that treatment with 300 milligrams (mg) of inxilane administered subcutaneously (sc) as inxilane sodium initially (day 1), day 90, and every 6 months thereafter will significantly reduce the risk of 4-point major adverse cardiovascular events (4P-MACE), defined as the composite of CV death, nonfatal myocardial infarction (MI), nonfatal ischemic stroke, and urgent coronary revascularization, compared with placebo in patients at high cardiovascular (CV) risk without prior major atherosclerotic cardiovascular disease (ASCVD) events.
[0313] method
[0314] The objective of this study is to evaluate the efficacy of 300 mg of inxilane sodium administered subcutaneously (sc) (equivalent to 284 mg of inxilane) compared with placebo in reducing the risk of 4P-MACE events in adult patients at high risk for a first major adverse cardiovascular event. Randomized participants will receive subcutaneous study medication (inxilane or placebo) on day 1, day 90, and then every 6 months. The overall trial duration is expected to be approximately 6.3 years, with the study continuing until at least 853 participants have experienced a clinical endpoint committee (CEC)-confirmed primary 4P-MACE (a composite of CV death, nonfatal MI, nonfatal ischemic stroke, and urgent coronary revascularization) and at least 638 participants across both treatment groups have experienced a CEC-confirmed 3P-MACE (a composite of CV death, nonfatal MI, and nonfatal ischemic stroke), and all participants have been followed for at least 3 years (dual-blind period).
[0315] Compared with placebo, Inxilan is expected to reduce the hazard rate of the 4P-MACE endpoint by at least 20% on average.
[0316] Inxilan is also expected to reduce the hazard rate of the 3P-MACE endpoint by at least 20% on average compared with placebo.
[0317] Appropriateness of efficacy assessment
[0318] 4P-MACE, 3P-MACE, and cardiovascular death are well-defined standard clinical assessments in clinical trials designed to demonstrate CV risk reduction. Assessment of events and laboratory tests related to secondary endpoints was consistent with the intended efficacy of Inxilan.
[0319] Study objectives and relevant endpoints
[0320]
[0321]
[0322]
[0323] Primary End Point
[0324] The primary endpoint was time to the first occurrence of 4P-MACE (a composite of CV death, nonfatal MI, nonfatal ischemic stroke, and urgent coronary revascularization).
[0325] Secondary End Points
[0326] Secondary endpoints considered for efficacy were:
[0327] • Time to first occurrence of 3P-MACE (CV death, nonfatal MI, and nonfatal ischemic stroke)
[0328] • Time to 4P-MACE (first and recurrent CV death, nonfatal MI, nonfatal ischemic stroke, and urgent coronary revascularization)
[0329] • Time to 3P-MACE (first and recurrent CV death, nonfatal MI, and nonfatal ischemic stroke)
[0330] • Time to CV death
[0331] • Time to all-cause death
[0332] Exploratory endpoints
[0333] Other cardiovascular (CV) endpoints assessed were as follows:
[0334] •CV deaths
[0335] • Nonfatal MI
[0336] • Non-fatal ischemic stroke
[0337] • Urgent coronary revascularization
[0338] • Composite of all-cause mortality, nonfatal MI, and nonfatal ischemic stroke
[0339] • Composite of all-cause death, nonfatal MI, nonfatal ischemic stroke, and urgent coronary revascularization
[0340] • A composite of coronary events (death from CHD, MI, unstable angina requiring hospitalization, and urgent / elective revascularization)
[0341] • Major adverse limb event (MALE)
[0342] • All-cause urgent revascularization
[0343] • All-cause CV hospitalizations, including MI hospitalizations and unstable angina hospitalizations
[0344] • Venous thromboembolism leading to hospitalization or death
[0345] • Total CV events (first and recurrent nonfatal MI, nonfatal ischemic stroke, hospitalization for unstable angina, heart failure, or MALE)
[0346] Other efficacy assessments
[0347] Other efficacy assessments will include total cholesterol, LDL-C, HDL-C, VLDL-C, non-HDL-C, Lp(a), and triglycerides. Participants must fast for 10 hours prior to lipid / lipoprotein assessments. Lipid profiles will be assessed according to the assessment schedule at each study visit after randomization (Day 1).
[0348] Patient population used in the study
[0349] The study will enroll 14,000 high-CV risk patients with LDL-C ≥ 70 mg / dL (1.81 mmol / L) but < 190 mg / dL (4.91 mmol / L) and no prior major ASCVD events.
[0350] Inclusion criteria
[0351] Participants eligible for inclusion in this study must meet all of the following criteria:
[0352] 1. Must provide signed informed consent before participating in the study
[0353] 2. Male or female aged ≥ 40 years but < 80 years
[0354] 3. At increased risk for a first MACE (ie, without a prior major ASCVD event), defined as any of the following:
[0355] a. Evidence of atherosclerotic CAD on CT or invasive coronary angiography, defined as stenosis ≥ 20% but < 50% in the left main coronary artery or ≥ 20% but < 70% in any major epicardial coronary artery
[0356] b. Coronary artery calcium (CAC) score ≥ 100 Agatston units obtained on CT scan – determined at any time prior to the screening visit
[0357] c. High 10-year ASCVD risk ≥ 20% (assessed using the pooled cohort equation)
[0358] d. Intermediate 10-year ASCVD risk 7.5% to < 20% (estimated using the pooled cohort equation) and the presence of at least two of the following risk-enhancing factors:
[0359] i. First-degree relative with a history of premature ASCVD (male, age < 55 years; female, age < 65 years)
[0360] ii. History of premature menopause before the age of 40
[0361] iii. History of maternal pregnancy complications (defined as a history of preeclampsia, gestational hypertension, or gestational diabetes)
[0362] iv. South Asian descent
[0363] v. Chronic inflammatory disorder (defined as rheumatoid arthritis, systemic lupus erythematosus, psoriasis covering ≥ 10% of body surface area, Crohn's disease, ulcerative colitis, or HIV / AIDS)
[0364] vi. High-sensitivity C-reactive protein (hsCRP) ≥ 2 mg / L – documented within the 12 months prior to the screening visit and in the absence of any underlying acute or inflammatory condition (including any chronic inflammatory disorder listed in criterion 3 dv above)
[0365] vii. Lipoprotein(a) ≥ 50 mg / dL or 125 nmol / L – determined at any time prior to the screening visit
[0366] viii. Estimated glomerular filtration rate (eGFR) < 60 mL / min / 1.73 m 2 – Recorded between the Screening Visit and the Randomization Visit
[0367] ix. Ankle-brachial index (ABI) < 0.9, no intermittent claudication symptoms
[0368] x. Metabolic syndrome: Increased waist circumference, elevated triglycerides, elevated blood pressure, elevated blood glucose, and low HDL-C are factors – 3 or more in total, recorded between the screening visit and the randomization visit
[0369] 4. If on background LLT, the dose should be stable for at least 4 weeks prior to the screening visit, and the participant should be willing to remain on this background therapy throughout the study.
[0370] 5. LDL-C ≥ 70 mg / dL (≥ 1.81 mmol / L) but < 190 mg / dL (< 4.91 mmol / L) at the screening visit
[0371] Exclusion criteria
[0372] Patients were excluded from the study if they met any of the following exclusion criteria:
[0373] 1. History of a major ASCVD event was defined as any of the following:
[0374] a. Acute coronary syndrome (ACS) within 12 months before randomization, or
[0375] b. Previous myocardial infarction at any time before randomization, or
[0376] c. Previous ischemic stroke at any time before randomization, or
[0377] d. Symptomatic peripheral arterial disease (PAD) at any time before randomization, as evidenced by intermittent claudication, previous revascularization, or amputation due to atherosclerotic disease
[0378] 2. History or plan of ischemia-driven revascularization in the coronary or extracoronary arterial bed before randomization
[0379] 3. No coronary atherosclerosis was found on CT angiography or invasive coronary angiography within 2 years before randomization
[0380] 4. Coronary artery calcification (CAC) score of 0 obtained 2 years before randomization.
[0381] 5. Active liver disease or liver dysfunction, defined as AST or ALT ≥3x ULN on central laboratory testing at the screening visit
[0382] 6. Current or planned kidney dialysis or transplantation
[0383] 7. Previous (within 90 days before the screening visit), current, or planned treatment with mAb targeting PCSK9 (e.g., evolocumab, alirocumab)
[0384] 8. Received Inksilan or any other non-mAb PCSK9 targeted therapy as an investigational drug or marketed drug within 2 years before randomization
[0385] 9. Severe concomitant non-cardiovascular diseases are expected to reduce life expectancy to less than 5 years
[0386] 10. Patients who are taking other investigational drugs within 5 half-lives or 30 days (e.g., for small molecules) at the time of recruitment, or whose expected pharmacodynamic effects have not yet returned to baseline (e.g., for biologics), whichever is longer;
[0387] 11. Any history of allergy to any study drug or its excipients or similar chemical class drugs
[0388] 12. Any surgical or medical condition that the investigator believes may put the participant at increased risk for participating in the study, or may prevent the participant from complying with the study requirements or completing the study
[0389] 13. Unwillingness or inability (e.g., physical or cognitive) to comply with study procedures (including attending study visits, fasting blood draws, and adhering to study treatment regimen) and drug administration (injections) and schedules
[0390] 14. Pregnant or lactating women
[0391] 15. Women of childbearing potential, defined as all women who are physiologically capable of becoming pregnant, unless they are using effective contraception while receiving study treatment.
[0392] 16. Personnel directly involved in the implementation of this plan, including investigators and their families
[0393] The screening algorithm of the screening strategy is summarized as follows Figure 1 shown.
[0394] Study Treatment
[0395] Study Design
[0396] The research design is shown in Figure 2. Figure 2 shown.
[0397] Study drugs and control drugs
[0398]
[0399] Additional study treatments
[0400] No treatment other than the study drug and the control drug was included in this trial.
[0401] Treatment group (arm / group)
[0402] Participants will be assigned in a 1:1 ratio to one of the following two treatment groups at the Day 1 (baseline) visit:
[0403] • Inxilane sodium 300 mg (equivalent to approximately 284 mg Inxilane) subcutaneously
[0404] • Matching placebo s.c.
[0405] Each participant will receive a blinded subcutaneous injection of Inxilan or placebo on day 1, a second blinded injection of Inxilan or placebo at month 3, and then every 6 months thereafter.
[0406] Duration of treatment
[0407] The study duration is expected to be approximately 6.3 years. However, as this is an event-driven trial, treatment duration will vary depending on when participants enter the study. The study will be completed when at least 853 participants have experienced a major 4P-MACE confirmed by the Clinical Endpoints Committee (CEC), and at least 638 participants have experienced a CEC-confirmed 3P-MACE in both treatment groups, and all randomized participants have completed 3 years of follow-up. Participants may discontinue study medication prematurely for safety reasons and / or at the investigator's or participant's discretion. If this occurs, they will continue to be followed in the study unless they withdraw informed consent.
[0408] Instructions for prescribing and taking study treatment
[0409] Study medication and control medication will not be dispensed to participants. Administration of study medication will be performed by the investigator or a qualified healthcare professional.
[0410] Participants will receive a single subcutaneous injection of 300 mg of incretin sodium or placebo at the scheduled time points described in the activity schedule. The injection will be administered after all other study assessments have been completed at the visit.
[0411] The preferred injection site is the abdomen. Alternative injection sites include the upper arm or thigh. Injections should not be given in areas with active skin disease or damage (such as sunburn, rash, inflammation, or skin infection).
[0412] Scientific rationale for study design
[0413] This study aimed to evaluate the efficacy and safety of inxilan sodium 300 mg in reducing the risk of 4P-MACE (i.e., primary prevention) in participants with high CV risk but no prior major ASCVD events, who had elevated LDL-C levels despite taking guideline-recommended LLTs. This study design was the most appropriate trial to answer the clinical questions of interest. The entry criterion of LDL-C ≥ 70 mg / dL (1.81 mmol / L) was based on multiple lipid treatment guidelines for patients at high ASCVD risk (Grundy et al. 2019, Mach et al. 2020).
[0414] Justification of dosage
[0415] The established dosing regimen for Leqvio sodium in adults is 300 mg administered subcutaneously on day 1, month 3 (day 90), and every six months thereafter. This dose and dosing regimen were extensively studied in a Phase III clinical program that exposed 1,833 patients to Leqvio and will be used in this study to provide maximum efficacy and an acceptable safety profile. Additionally, this dose and dosing regimen is approved for lowering LDL-C in the United States, Europe, and other countries worldwide (Leqvio USPI, Leqvio SmPC).
[0416] This dose and dosing schedule were selected based on data from the Phase II dose-finding study (ORION-1). ORION-1 tested different doses of incretin sodium (up to 500 mg), administered as a single dose or multiple doses spaced 90 days apart (Ray et al. 2019). This study found that a regimen containing two 300 mg induction doses of incretin sodium resulted in the greatest reduction in LDL-C from baseline to day 180 (52.6%). This dose and schedule also resulted in the greatest reduction in PCSK9 from baseline to day 180 (69.1%). A Phase I study (ALN-PCSSC-001) investigated doses up to 900 mg and found no clinically significant additional benefit above 300 mg (Fitzgerald et al. 2017), further supporting the 300 mg dose. Furthermore, a 300 mg dose of inxilan sodium was studied in participants with mild, moderate, and severe renal impairment and mild and moderate hepatic impairment, and no clinically meaningful differences in LDL-C and PCSK9 reductions were observed compared with those observed in other participant populations, without the need for dose adjustment. Therefore, this dosing regimen is effective in patients with both renal and hepatic impairment.
[0417] Three large pivotal Phase III clinical trials (ORION-9, -10, -11) in adults with ASCVD, ASCVD-equivalent risk, and HeFH (Wright et al. 2021) demonstrated that the dosing regimen used in this study (300 mg of inxilamine sodium administered subcutaneously on day 1, month 3 (day 90), and every 6 months thereafter) resulted in placebo-adjusted percentage reductions in LDL-C from baseline of 48% to 52% at day 510, with time-adjusted mean reductions of 44% to 54% sustained over 18 months (Raal et al. 2020, Ray et al. 2020). This dose and regimen were well tolerated, with a safety profile similar to placebo, although inxilamine was associated with more injection-site reactions than placebo.
[0418] Treatment duration will continue throughout the study, which is expected to be approximately 6.3 years. The study will be completed when the target number of events and minimum follow-up have occurred.
[0419] Rationale for selecting background therapy
[0420] Participants should meet the LLT care background criteria as defined by local practice guidelines. Although practice guidelines vary between countries, some general principles were used in this protocol and are consistent with the most recent US guidelines for blood cholesterol management (Grundy et al. 2019).
[0421] More specifically, patients entering the study were required to have received at least 4 weeks of moderate-intensity statin therapy before the screening visit if they had evidence of CAD (inclusion criterion 3a), a CAC score ≥ 100 Agatston units (inclusion criterion 3b), or diabetes.
[0422] According to the latest US guidelines (Grundy et al. 2019), and to minimize ASCVD risk, high-intensity statin therapy is strongly recommended for the following categories of patients:
[0423] Patients entering the trial with a high 10-year ASCVD risk ≥ 20% (inclusion criterion 3c);
[0424] Patients with an intermediate 10-year ASCVD risk (≥ 7.5-< 20%) plus two risk-enhancing factors were reclassified into the high 10-year ASCVD risk category according to the guidelines (inclusion criterion 3d); and
[0425] Patients with diabetes and multiple ASCVD risk factors (assessed according to clinical judgment) regardless of other inclusion criteria.
[0426] If applicable, these recommendations for high-intensity statin therapy can be adjusted based on local practice guidelines and clinical judgment.
[0427] In all cases, one or more doses of any LLT should have been stable for at least 4 weeks prior to the screening visit and could not include PCSK9-targeted therapy, and participants should be willing to maintain this background LLT for the entire duration of the study.
[0428] During the study, the sponsor will ensure that approximately 70% of randomized participants enter the trial with a statin as part of their background therapy.
[0429] Rationale for selecting a comparator (comparator / placebo)
[0430] This placebo-controlled trial, in addition to standard of care, provides robust evidence of the effects of Inxilan on clinical events, safety, and tolerability. The use of placebo as a comparator is justified because all randomized participants will be treated according to local practice guidelines prior to study entry and throughout the study. All participants will receive standard of care, including but not limited to dietary advice provided by the investigator, antihypertensive medications, antihyperglycemic medications (if appropriate), and antiplatelet therapy, as clinically indicated.
[0431] Concomitant therapy
[0432] Concomitant lipid-lowering therapy
[0433] Participants were required to maintain their background LLT unchanged (ie, no changes in medication or dose) during the study.
[0434] Changes to background LLTs are permitted only if:
[0435] • If an AE occurs that requires interruption, dose reduction, or discontinuation of the background LLT, such changes may be made.
[0436] If LDL-C increases above a predefined threshold, a dose increase or the addition of another background LLT is permitted. drug
[0437] The treatments shown in the table below are not permitted after screening.
[0438] banned drugs
[0439]
[0440]
[0441]
[0442] analyze
[0443] One or more primary endpoints / one or more estimated value analyses
[0444] The primary objective of the study was to demonstrate the superiority of Inxilan compared with placebo in reducing the risk of 4P-MACE (CV death, non-fatal MI, non-fatal ischemic stroke, and urgent coronary revascularization).
[0445] Definition of the primary endpoint
[0446] The primary endpoint of the study was time to the first occurrence of any component of 4P-MACE (a composite endpoint consisting of CV death, nonfatal MI, nonfatal ischemic stroke, and urgent coronary revascularization).
[0447] Time to event was calculated as the number of days from randomization to the occurrence of the primary end-point event.
[0448] Statistical models, assumptions, and analytical methods
[0449] The main statistical hypotheses to be tested are:
[0450] H0:λ 英克西兰 / λ 安慰剂 ≥ 1 compared to H a :λ 英克西兰 / λ 安慰剂 < 1,
[0451] where λ 英克西兰 and λ 安慰剂 are the hazard rates of the first 4P-MACE in the Inxilan group and the placebo group, respectively. 英克西兰 / λ 安慰剂 is the hazard ratio (HR) of Inxilan relative to placebo.
[0452] The primary efficacy endpoint will be analyzed using a Cox proportional hazards model stratified by region and baseline statin status (presence / absence), with treatment group as the only factor in the model. Estimated hazard ratios (HRs) and corresponding unadjusted two-sided 95% confidence intervals from the Cox regression model will be presented separately. The primary hypothesis will be tested using a log-rank test stratified by region and baseline statin status (presence / absence). P-values for testing these hypotheses will be provided. If the p-value is less than or equal to the appropriate alpha level for the current phase, superiority of Inxilan over placebo can be claimed.
[0453] The overall type I error rate for the study will be controlled at 0.025 (one-sided) for testing of the primary and secondary end points. The significance level for the final analysis will be adjusted to account for the alpha level used in the interim efficacy analysis.
[0454] Supplementary analysis
[0455] The survival function for each treatment group will be estimated by the Kaplan–Meier method, and Kaplan–Meier or cumulative incidence curves will show the primary composite end point and its components separately by treatment group.
[0456] The frequency and percentage of participants achieving the primary composite endpoint will be provided by treatment group. The components of the primary composite endpoint will also be summarized descriptively to assess their contribution to the overall treatment effect. Treatment comparisons based on marginal time to fatal and nonfatal MI or fatal and nonfatal stroke will be analyzed using the same Cox regression model as for the primary analysis.
[0457] The following supplementary analyses of the primary endpoint were also performed:
[0458] •The primary analysis was modified using the investigator-reported primary endpoint (ie, time to the first occurrence of investigator-reported 4P-MACE).
[0459] •The primary analysis was modified using covariate-adjusted analyses (eg, adjusting baseline risk prediction according to the pooled cohort equation).
[0460] •The primary endpoint will be analyzed using the Fine-Gray partial distribution hazard model, with non-CV death modeled as a competing risk. Cumulative incidence functions considering non-CV death as a competing risk will also be presented.
[0461] • A modification of the primary analysis in which deaths from unknown causes were categorized as CV deaths.
[0462] If necessary, additional supplementary analyses can be planned and documented in the Statistical Analysis Plan (SAP).
[0463] Subgroup analysis
[0464] Subgroup analyses can be performed to assess the homogeneity of treatment effects across demographic and baseline characteristics. Subgroups considered include:
[0465] •Age groups (< 65 years, 65 to < 75 years, and ≥ 75 years)
[0466] •gender
[0467] •Race
[0468] •area
[0469] • Baseline BMI (< 30, 30 to < 35, and ≥ 35 kg / m 2 )
[0470] • Baseline eGFR (< 30, 30 to < 60, and ≥ 60 mL / min / 1.73 m2 )
[0471] • Baseline diabetes (Y / N)
[0472] • Baseline current smoker (Y / N)
[0473] • Baseline hypertension (Y / N)
[0474] • Baseline LDL-C (< 100 and ≥ 100 mg / dL)
[0475] • Baseline Lp(a) (median, quartiles, and specific cutoffs previously determined in SAP by database locking)
[0476] • Baseline triglycerides (< 150, 150 to < 200, and ≥ 200 mg / dL)
[0477] • Baseline hsCRP (< 2 and ≥ 2 mg / dL)
[0478] • Baseline statin intensity (high, moderate, no statin)
[0479] The estimated HR and two-sided 95% confidence interval for each subgroup will be derived from a Cox proportional hazards model with treatment, subgroup, and treatment by subgroup as covariates. Nominal p-values for treatment by subgroup interactions will also be presented. No adjustments will be made for multiple comparisons. In addition, the frequency and percentage of subjects achieving the primary composite endpoint will be presented by treatment group within each subgroup.
[0480] One or more secondary endpoints / one or more estimated value analyses
[0481] Efficacy and / or one or more pharmacodynamic endpoints
[0482] Five secondary endpoints were considered for efficacy:
[0483] • Time to first occurrence of 3P-MACE (CV death, nonfatal MI, and nonfatal ischemic stroke)
[0484] • Time to 4P-MACE (first and recurrent CV death, nonfatal MI, nonfatal ischemic stroke, and urgent coronary revascularization)
[0485] • Time to 3P-MACE (first and recurrent CV death, nonfatal MI, and nonfatal ischemic stroke)
[0486] • Time to CV death
[0487] • Time to all-cause death
[0488] Unless otherwise stated, the endpoints determined above will be used for analysis.
[0489] The corresponding assumptions for the secondary endpoints are as follows:
[0490] • Time to first occurrence of 3P-MACE
[0491] •H1:λ 英克西兰 / λ 安慰剂 ≥ 1 compared to H a1 :λ 英克西兰 / λ 安慰剂 < 1.
[0492] • Time to 4P-MACE (first and recurrence)
[0493] •H2: The rate ratio of Inxilan / placebo ≥ 1 compared with H a2 : The rate ratio of Inxilan / placebo was < 1.
[0494] • Time to 3P-MACE (first and recurrence)
[0495] •H3: The rate ratio of Inxilan / placebo is ≥ 1 compared with H a3 : The rate ratio of Inxilan / placebo was < 1.
[0496] • Time to CV death
[0497] •H4: λ 英克西兰 / λ 安慰剂 ≥ 1 compared to H a4 :λ 英克西兰 / λ 安慰剂 < 1.
[0498] • Time to all-cause death
[0499] •H5: λ 英克西兰 / λ 安慰剂 ≥ 1 compared to H a5 :λ 英克西兰 / λ 安慰剂 < 1.
[0500] After successfully rejecting the primary endpoint hypothesis (H0), H1 and H2 will be tested using the Benjamini-Hochberg procedure at the alpha level available at the current stage. If both H1 and H2 are rejected, H3, H4, and H5 will be tested sequentially under the hierarchical testing procedure at the alpha level available at the current stage. Figure 3 The testing procedure to be followed is presented graphically in . Note: α is passed to test H3 only if both H1 and H2 are rejected.
[0501] The same Cox regression model as the primary efficacy endpoint will be used to analyze the secondary efficacy endpoints, i.e., the time to the first occurrence of 3P-MACE, the time to CV death, and the time to all-cause death. The estimated HR and the corresponding unadjusted two-sided 95% confidence interval from the Cox regression model will be provided separately. The nominal p value for testing H1, H4, and H5 will also be provided.
[0502] Secondary efficacy endpoints (time to 4P-MACE and time to 3P-MACE) will be analyzed using the semiparametric proportional rate model (LWYY model) proposed by Lin et al., 2000. Estimated rate ratios and their 95% confidence intervals will be provided, along with nominal p-values for testing the corresponding hypotheses H2 and H3.
[0503] Safety endpoints
[0504] The study will collect AEs of interest, which include all SAEs, all AEs leading to study drug discontinuation, and AEs of special interest (AEs of new-onset diabetes in participants without diabetes at baseline). In addition, liver function tests will be collected from participants with AST or ALT > 1x ULN at the screening visit (estimated to be approximately 5% of the study population) and a randomly selected subset (approximately 15% of the study population) during follow-up until the EOS visit.
[0505] The treatment period lasted from the date of the first administration of study treatment to 180 days after the date of the last actual administration of any study treatment.
[0506] result
[0507] This study is expected to demonstrate that 300 mg of inxilamine sodium (equivalent to 284 mg of inxilamine) administered subcutaneously on day 1, day 90, and then every 6 months is effective in reducing the risk of 4P-MACE compared with placebo in adults who have not experienced a major ASCVD event.
[0508] The study is also expected to demonstrate that subcutaneous (sc) administration of 300 mg of inxilane sodium (equivalent to 284 mg of inxilane) on day 1, day 90, and then every 6 months is effective in reducing the risk of 3P-MACE (CV death, nonfatal MI, or nonfatal ischemic stroke), CV death, and all-cause mortality compared with placebo in adults who have not experienced a major ASCVD event.
[0509] The study is also expected to demonstrate that inxilane sodium 300 mg (equivalent to 284 mg inxilane) administered subcutaneously on day 1, day 90, and then every 6 months is effective in reducing the risk of CV death compared with placebo in adults who have not experienced a major ASCVD event.
[0510] The study is also expected to demonstrate that 300 mg of inxilane sodium (equivalent to 284 mg of inxilane) administered subcutaneously on day 1, day 90, and then every 6 months is effective in reducing the risk of all-cause mortality compared with placebo in adults who have not experienced a major ASCVD event.
[0511] References
[0512] Achenbach S, Raggi P (2010) Imaging of coronary atherosclerosis bycomputed tomography; European Heart Journal, Volume 31, Issue 12, June 2010, Pages 1442–1448, https: / / doi.org / 10.1093 / eurheartj / ehq150
[0513] Benjamin EJ, Muntner P, Alonso A, et al (2019) Heart Disease and Stroke Statistics - 2019 Update: A report from the American HeartAssociation. Circulation; 139(10):e56-e528.
[0514] D'agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care. Circulation. 2008 Feb 12;117:743-53. PMID:18212285.
[0515] Fitzgerald K, White S, Borodovsky A, et al (2017) A highly durableRNAi therapeutic inhibitor of PCSK9. N Engl J Med; 376(1):41-51.
[0516] Goff DC, Lloyd-Jones DM, Bennett G, et al (2014) 2013 ACC / AHAguideline on the assessment of cardiovascular risk: a report of the AmericanCollege of Cardiology / American Heart Association Task Force on PracticeGuidelines. Circulation; 129(25 Suppl 2):S49-73.
[0517] Grundy SM, Brewer HB, Cleeman JI, et al (2004) Definition ofmetabolic syndrome: Report of the National Heart, Lung, and Blood Institute / American Heart Association conference on scientific issues related todefinition. Circulation; 109(3):433-8.
[0518] Grundy SM, Stone NJ, Bailey AL, et al (2019) 2018 AHA / ACC / AACVPR / AAPA / ABC / ACPM / ADA / AGS / APhA / ASPC / NLA / PCNA guideline on the management of bloodcholesterol: A report of the American College of Cardiology / American HeartAssociation Task Force on clinical practice guidelines. J Am Coll Cardiol; 73(24):3158-3209.
[0519] Leqvio SmPC (2020) Summary of Product Characteristics. Leqvio(inclisiran) 284 mg solution for injection. Novartis Europharm Limited,Dublin, Ireland. Updated 19 Aug 2022.
[0520] Leqvio USPI (2021). Leqvio (inclisiran) 284 mg injection forsubcutaneous use. US Prescribing Information. Novartis PharmaceuticalsCorporation, East Hanover, NJ. Revised Dec 2021.
[0521] Lin DY, Wei LJ, Yang I, et al (2000) Semiparametric regression forthe mean and rate functions of recurrent events. J R Statist Soc B; 62(4):711-30.
[0522] Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC Jr, Sperling LS,Virani SS, Blumenthal RS. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: aspecial report from the American Heart Association and American College ofCardiology; JACC Nov 2018, 25711; DOI:10.1016 / j.jacc.2018.11.005
[0523] Mach F, Baigent C, Catapano AL, et al (2020) 2019 ESC / EAS Guidelinesfor the management of dyslipidaemias: lipid modification to reducecardiovascular risk. Eur Heart J; 41(1):111-88.
[0524] Raal FJ, Kallend D, Ray KK, et al (2020) Inclisiran for the treatmentof heterozygous familial hypercholesterolemia. N Engl J Med; 382(16):1520-30.
[0525] Randomized Trial Assessing the Effects of Inclisiran on ClinicalOutcomes Among People With Cardiovascular Disease (ORION-4). Available from: / / clinicaltrials.gov / ct2 / show / NCT03705234 (Accessed 29 Jun 2022).
[0526] Ray KK, Stoekenbroek RM, Kallend D, et al (2019) Effect of 1 or 2doses of inclisiran on low-density lipoprotein cholesterol levels: One-yearfollow-up of the ORION-1 randomized clinical trial. JAMA Cardiol; 4(11):1067-75.
[0527] Ray KK, Wright RS, Kallend D, et al (2020) Two phase 3 trials ofinclisiran in patients with elevated LDL cholesterol. N Engl J Med; 382(16):1507-19.
[0528] Recommended INN: List 76 from the WHO Drug Information, Vol. 30, No.3, 2016, pages 504-506, inclisiran.
[0529] Remington: The Science and Practice of Pharmacy, 23rd Edition, 2020
[0530] Study of Inclisiran to Prevent Cardiovascular (CV) Events inParticipants With Established Cardiovascular Disease (VICTORION-2P).Available from: / / clinicaltrials.gov / ct2 / show / NCT05030428 (Accessed 29 Jun2022).
[0531] WHO (2019) Cardiovascular diseases (CVDs). Available from: / / who.int / health-topics / cardiovascular-diseases#tab=tab_1 (Accessed 29 Jun 2022).
[0532] Wright RS, Ray KK, Raal FJ, et al (2021) Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol; 77(9):1182-93.
[0533] sequence
[0534] SEQ ID NO: 1
[0535] 5'-ACAAAAGCAAAACAGGUCUAGAA - 3'
[0536] SEQ ID NO: 2
[0537] 5'-CUAGACCUUUUGCUUUUGU - 3'
[0538] SEQ ID NO: 3
[0539] 5'-asCfsaAfAfAfgCfaAfaAfcAfgGfuCfuagsasa-3', where a, g, c, and u are 2'-O-methyl (2'-OMe) A, G, C, or U; Af, Gf, Cf, or Uf is 2'-fluoro A, G, C, or U; and s is a phosphorothioate linkage
[0540] SEQ ID NO: 4
[0541] 5'-csusagacCfuGfudTuugcuuuugu-3', where a, g, c, and u are 2'-O-methyl (2'-OMe) A, G, C, or U; Af, Gf, Cf, or Uf are 2'-fluoro A, G, C, or U; dT is 2'-deoxythymidine; and s is a phosphorothioate linkage
Claims
1. A method of reducing the risk of major adverse cardiovascular events (MACE) in subjects who have not experienced a major atherosclerotic cardiovascular disease (ASCVD) event, Wherein the MACE is cardiovascular death, non-fatal myocardial infarction (MI), non-fatal ischemic stroke or urgent coronary revascularization, wherein the method comprises administering to the subject an interfering ribonucleic acid (RNAi) agent, wherein the RNAi agent comprises: an antisense strand comprising the nucleotide sequence 5'-asCfsaAfAfAfgCfaAfaAfcAfgGfuCfuagsasa-3' (SEQ ID NO: 3), and a sense strand comprising the nucleotide sequence 5'-csusagacCfuGfudTuugcuuuugu-3' (SEQ ID NO: 4), wherein a, g, c, and u are 2'-O-methyl (2'-OMe) modified A, G, C, and U nucleotides, respectively; Af, Gf, Cf, and Uf are 2'-fluoro A, G, C, and U modified nucleotides, respectively; dT is a deoxythymidine nucleotide, and s is a phosphorothioate linkage; and wherein the sense strand is conjugated to at least one ligand.
2. The method of claim 1, wherein the ligand comprises the following structure: 。 3. The method of claim 1 or claim 2, wherein the ligand is conjugated to the 3' end of the sense strand.
4. The method of claim 3, wherein the RNAi agent is conjugated to the ligand as shown in the following schematic: Wherein X is O or S. The method of claim 4 , wherein X is O.
6. The method of any one of claims 1-5, wherein the subject is at increased risk for a first MACE.
7. The method of claim 6, wherein the increased risk of a first MACE is defined as any of the following: a) Evidence of atherosclerotic CAD on CT or invasive coronary angiography, defined as stenosis of ≥ 20% but < 50% in the left main coronary artery or ≥ 20% but < 70% in any major epicardial coronary artery; b) Coronary artery calcification (CAC) score obtained by CT scan ≥ 100 Agatston units; c) high 10-year ASCVD risk ≥ 20% (assessed using the pooled cohort equation); d) Intermediate 10-year ASCVD risk 7.5% to < 20% (estimated using the pooled cohort equation) and the presence of at least two of the following risk-enhancing factors: i. First-degree relative with a history of premature ASCVD (male, age < 55 years; female, age < 65 years) ii. History of premature menopause before the age of 40 iii. History of maternal pregnancy complications (defined as a history of preeclampsia, gestational hypertension, or gestational diabetes) iv. South Asian descent v. Chronic inflammatory disorder (defined as rheumatoid arthritis, systemic lupus erythematosus, psoriasis covering ≥ 10% of body surface area, Crohn's disease, ulcerative colitis, or HIV / AIDS) vi. High-sensitivity C-reactive protein (hsCRP) ≥ 2 mg / L – documented within the 12 months prior to the screening visit and in the absence of any underlying acute or inflammatory condition (including any chronic inflammatory disorder listed in Criterion 3 DV) vii. Lipoprotein(a) ≥ 50 mg / dL or 125 nmol / L viii. Estimated glomerular filtration rate (eGFR) < 60 mL / min / 1.73 m 2 ix. Ankle-brachial index (ABI) < 0.9 and no intermittent claudication symptoms; or x. Metabolic syndrome.
8. The method of any one of claims 1-7, wherein the subject has an LDL-C level of ≥ 70 mg / dL (≥ 1.81 mmol / L) but < 190 mg / dL (< 4.91 mmol / L).
9. The method of any one of claims 1-8, wherein the subject is being or has been treated with background lipid-lowering therapy (LLT).
10. The method of any one of claims 1-9, wherein the subject has not been or is not being treated with background lipid-lowering therapy (LLT).
11. The method of any one of claims 1-10, wherein the subject has not been treated with an additional PCSK9-targeted therapy prior to administration of the RNAi agent.
12. The method of any one of claims 1-10, wherein the subject has been treated with an additional PCSK9-targeted therapy prior to administration of the RNAi agent.
13. The method of any one of claims 1-12, wherein the subject has not experienced MACE at any time prior to administration of the RNAi agent.
14. The method of any one of claims 1-13, wherein the major ASCVD event is defined as any one of the following: a. Acute coronary syndrome (ACS) at any time before administration of the RNAi agent, eg, ACS within about 12 months before administration of the RNAi agent; b. myocardial infarction at any time before administration of the RNAi agent; c. ischemic stroke at any time before administration of the RNAi agent; or d. Symptomatic peripheral arterial disease (PAD) at any time prior to administration of the RNAi agent, such as evidenced by intermittent claudication, prior revascularization, or amputation due to atherosclerotic disease.
15. The method of any one of claims 1-14, wherein the subject has no history of ischemia-driven revascularization in the coronary or extracoronary arterial bed prior to administration of the RNAi agent.
16. The method of any one of claims 1-15, wherein the subject is free of coronary atherosclerosis on CT angiography or invasive coronary angiography within 2 years prior to administration of the RNAi agent.
17. The method of any one of claims 1-16, wherein the subject has not achieved a coronary artery calcification (CAC) score of 0 within 2 years prior to administration of the RNAi agent.
18. The method of any one of claims 1-17, wherein the subject does not have active liver disease or liver dysfunction, e.g., identified as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than or equal to 3 times the upper limit of normal (ULN).
19. The method of any one of claims 1-18, wherein the subject is on a diet aimed at improving lipid levels, maximally tolerated statin therapy, and / or low-density lipoprotein lowering therapy.
20. The method of any one of claims 1-19, wherein administration of the RNAi agent reduces low-density lipoprotein cholesterol (LDL-C) levels in the subject.
21. The method of any one of claims 1-20, wherein the method comprises a loading phase and a maintenance phase.
22. The method of claim 21, wherein the loading phase comprises administering the RNAi agent in one or more doses.
23. The method of claim 21 or 22, wherein the loading phase comprises administering the RNAi agent in at least two doses, each dose separated by a time interval.
24. The method of any one of claims 21-23, wherein the loading phase comprises administering the RNAi agent in two doses separated by a time interval.
25. The method of claim 23 or 24, wherein the administration of each dose in the loading phase is separated by a time interval of about 90 days (3 months) to 180 days (6 months).
26. The method of any one of claims 23-25, wherein the administration of each dose in the loading phase is separated by a time interval of about 90 days (3 months).
27. The method of any one of claims 21-26, wherein the maintenance phase comprises administering the RNAi agent in one or more doses, each dose separated by a time interval.
28. The method of any one of claims 21-27, wherein the time interval between administration of each dose in the maintenance phase is from about 90 days (3 months) to about 270 days (9 months).
29. The method of any one of claims 21-28, wherein the time interval between administration of each dose in the maintenance phase is about 180 days (6 months).
30. The method of any one of claims 1-29, wherein the RNAi agent is administered initially, again at 3 months, and then every 6 months.
31. The method of any one of claims 21-30, wherein the duration of the maintenance phase is at least 1 year, preferably wherein the duration of the maintenance phase is at least 2 years, at least 3 years, at least 4 years, at least 5 years or at least 6 years.
32. The method of any one of claims 1-31, wherein the method comprises administering the RNAi agent subcutaneously (eg, into the abdomen, upper arm, or thigh) and / or intravenously.
33. The method of any one of claims 21-32, wherein the method comprises administering the RNAi agent intravenously during the loading phase and administering the RNAi agent subcutaneously during the maintenance phase.
34. The method of any one of claims 21-32, wherein the method comprises administering the RNAi agent intravenously for a first dose of the loading phase and administering the RNAi agent subcutaneously for each subsequent dose.
35. The method of any one of claims 21-34, wherein the RNAi agent is Inksilan, and wherein the method comprises: (a) a loading phase, which consists of administering Inxilan in two doses separated by an interval of approximately 90 days (3 months), followed by (b) A maintenance phase, which involves administering one or more doses of Inxilan, with each dose separated by an interval of approximately 180 days (6 months).
36. The method of claim 35, wherein Inxilan is administered subcutaneously.
37. The method of any one of claims 1-36, wherein the RNAi agent is administered in a sterile aqueous solution, for example in a volume of about 1.5 mL.
38. The method of claim 37, wherein the sterile aqueous solution contains sodium hydroxide and / or phosphoric acid.
39. The method of claim 37 or 38, wherein the pH of the sterile aqueous solution is about 7.
0.
40. The method of any one of claims 37-39, wherein the sterile aqueous solution is contained in a prefilled syringe for subcutaneous administration.
41. The method of any one of claims 1-40, wherein the RNAi agent is Inksilan.
42. The method of any one of claims 4-41, wherein each dose comprises about 284 mg of Inksilan (equivalent to a corresponding amount of Inksilan salt).
43. The method of any one of claims 4-41, wherein each dose comprises about 284 mg of Inxilane (equivalent to about 300 mg of Inxilane sodium).
44. The method of any one of claims 1-43, wherein a 284 mg dose of Inxilan (equivalent to about 300 mg of Inxilan sodium) is administered as a single subcutaneous injection initially, again at 3 months, and then every 6 months.
45. An RNAi agent for use in the method of any one of claims 1-44.
46. A pharmaceutical composition comprising a RNAi agent for use in the method of any one of claims 1-44.
